<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>Safety profile of DAAs regimens</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Patients 
     <italic>(N = 144)</italic>
    </th>
    <th>Group A 
     <italic>(N = 101)</italic>
    </th>
    <th>Group B 
     <italic>(N = 43)</italic>
    </th>
    <th>
     <bold>
      <italic>p-</italic>
     </bold>value
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>At least 1 adverse event,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>60 (41,6%)</td>
    <td>49 (48.5%)</td>
    <td>11 (25.6%)</td>
    <td>
     <bold>0.015</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>&gt; 2 adverse events,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>7 (4.8%)</td>
    <td>6 (5.9%)</td>
    <td>1 (2.3%)</td>
    <td>0.674</td>
   </tr>
   <tr>
    <td>
     <bold>Severe adverse events,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>10 (6.9%)</td>
    <td>8 (7.9%)</td>
    <td>2 (4.6%)</td>
    <td>0.723</td>
   </tr>
   <tr>
    <td>
     <bold>Adverse events leading to discontinuation,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>3 (2.1%)</td>
    <td>2 (1.9%)</td>
    <td>1 (2.3%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <bold>Skin reactions</bold>
     <sup>
      <bold>a</bold>
     </sup>
     <bold>,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>11 (7.6%)</td>
    <td>9 (8.9%)</td>
    <td>2 (4.6%)</td>
    <td>0.506</td>
   </tr>
   <tr>
    <td>
     <bold>Anemia,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>7 (4.8%)</td>
    <td>5 (4.9%)</td>
    <td>2 (4.6%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>Requiring erythropoietin</italic>
    </td>
    <td>2 (1.3%)</td>
    <td>2 (1.9%)</td>
    <td>0</td>
    <td/>
   </tr>
   <tr>
    <td>
     <italic>Requiring RBV dose adjustment</italic>
    </td>
    <td>4 (2.7%)</td>
    <td>2 (1.9%)</td>
    <td>2 (4.6%)</td>
    <td/>
   </tr>
   <tr>
    <td>
     <italic>Requiring hospitalization</italic>
    </td>
    <td>1 (0.7%)</td>
    <td>1 (0.9%)</td>
    <td>0</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>Gastrointestinal toxicity</bold>
     <sup>
      <bold>b</bold>
     </sup>
     <bold>,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>11 (7.6%)</td>
    <td>9 (8.9%)</td>
    <td>2 (4.6%)</td>
    <td>0.506</td>
   </tr>
   <tr>
    <td>
     <bold>Cardiac disorders</bold>
     <sup>
      <bold>c</bold>
     </sup>
     <bold>,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>6 (4.1%)</td>
    <td>5 (4.9%)</td>
    <td>1 (2.3%)</td>
    <td>0.669</td>
   </tr>
   <tr>
    <td>
     <bold>Neurological symtomps,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>26 (18.0%)</td>
    <td>20 (19.8%)</td>
    <td>6 (13.9%)</td>
    <td>0.483</td>
   </tr>
   <tr>
    <td>
     <italic>Asthenia</italic>
    </td>
    <td>15 (10.4%)</td>
    <td>12 (11.8%)</td>
    <td>3 (6.9%)</td>
    <td>0.553</td>
   </tr>
   <tr>
    <td>
     <italic>Headache</italic>
    </td>
    <td>10 (6.9%)</td>
    <td>9 (8.9%)</td>
    <td>1 (2.3%)</td>
    <td>0.281</td>
   </tr>
   <tr>
    <td>
     <italic>Insomnia</italic>
    </td>
    <td>8 (5.5%)</td>
    <td>6 (5.9%)</td>
    <td>2 (4.6%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>Amnesia</italic>
    </td>
    <td>1 (0.7%)</td>
    <td>1 (0.9%)</td>
    <td>0</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>Seizures</italic>
    </td>
    <td>1 (0.7%)</td>
    <td>0</td>
    <td>1 (2.4%)</td>
    <td>0.298</td>
   </tr>
   <tr>
    <td>
     <bold>Psychiatric symtomps,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>8 (5.5%)</td>
    <td>8 (7.9%)</td>
    <td>0</td>
    <td>0.105</td>
   </tr>
   <tr>
    <td>
     <italic>Anxiety</italic>
    </td>
    <td>1 (0.7%)</td>
    <td>1 (0.9%)</td>
    <td>0</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>Mood disorders</italic>
    </td>
    <td>7 (4.8%)</td>
    <td>7 (6.9%)</td>
    <td>0</td>
    <td>0.103</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Legend:</italic>
   <sup>a</sup>-rash, pruritus, photosensitivity;
  </p>
  <p>
   <sup>b</sup>- diarrhea/constipation, dyspepsia, nausea;
  </p>
  <p>
   <sup>c</sup>-hyper/hypotension, arrhythmias
  </p>
 </table-wrap-foot>
</table-wrap>
